• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Shorter surveillance follow-up for stage I seminoma may be sufficient

byDavid WangandMarc Succi, MD
July 27, 2014
in Chronic Disease, Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A large, retrospective, population-based study of stage I seminoma patients followed by active surveillance post-orchiectomy demonstrated that the majority of relapses occurred within the first 5 years. 

2. The most important prognostic factor for stage I seminoma relapse wa tumor size. 

Evidence Rating Level: 3 (Average)        

Study Rundown: Guidelines for the use of active surveillance in stage I seminoma are highly variable. There has been no consensus as recommendations vary between 5 years post-orchiectomy to life-long follow-up. The authors of this study retrospectively analyzed survival outcomes of 1954 stage I seminoma patients managed by active surveillance and followed for at least 5 years. The results demonstrated that 369/1954 (18.9%) patients experienced relapse. However, the majority of relapses occurred within the first 5 years (median: 13.7 months). Furthermore, nearly all of the relapsing patients belonged to a good prognostic group. Overall, the disease specific survival and overall survival at 15 years were 99.3% and 91.6%, respectively. Multivariate analysis demonstrated that tumor size was the most important prognostic factor for seminoma relapse. This study is the largest cohort of stage I seminoma patients and the results of this study support the guidelines of a 5-year follow-up program post-orchiectomy to avoid unnecessary imaging. However, the study is limited by the retrospective design and additional prospective studies will be required before specific guidelines can be implemented.

Click to read the study in European Urology

Relevant Reading: Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer

In-Depth [retrospective cohort]: This retrospective review analyzed 1954 adult patients diagnosed with stage I seminoma between 1984 and 2007 as part of the Danish Testicular Cancer database (DaTeCa). The primary outcomes were disease-specific survival (DSS), overall survival (OS), and prognostic factors for relapse.  The median follow-up time was 15.1 years. Overall, 369 patients relapsed over the observation period, 95% (353/369) of which occurred within the first 5 years of follow-up. Kaplan-Meier analysis demonstrated that DSS after 5, 10, and 15 years was 99.6%, 99.4% and 99.3% respectively and OS after 15 years was 91.6%. Multivariate analysis demonstrated that tumor size was the most significant prognostic factor for relapse (HR: 1.59, 95% CI: 1.31-1.92, p<0.0001). Invasion of epididymis (HR: 1.57, 95%CI: 1.04-2.38) and vascular invasion (HR: 1.41, 95% CI: 1.05-1.89) were both statistically significant risk factors for relapse, provided the other was removed from the multivariate model.

RELATED REPORTS

Certain cancer therapy innovations not associated with decreasing mortality

More from this author: No association found between time to appendectomy and appendix perforation, Obesity linked with prostate cancer progression, Use of 5α-reductase inhibitors may not increase risk of high-grade prostate cancer, Asymptomatic H. pylori eradication decreased gastric cancer in Asian populations, Gender differences in white matter integrity may affect post-traumatic brain injury 

Image: CC/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: seminomatesticular caner
Previous Post

Oocyte vitrification not associated with adverse obstetric or perinatal outcomes

Next Post

Protocol-driven Neonatal Abstinence Syndrome care effective

RelatedReports

Certain cancer therapy innovations not associated with decreasing mortality
Chronic Disease

Certain cancer therapy innovations not associated with decreasing mortality

August 30, 2013
Next Post
Impaired brain growth in preterm infants linked with delayed cognitive development

Protocol-driven Neonatal Abstinence Syndrome care effective

Buccal administration of dextrose gel effective for neonatal hypoglycemia

Impaired brain growth in preterm infants linked with delayed cognitive development

Study lends support for interferon-free treatment of hepatitis C

Novel pill-only regimens effective against hepatitis C [COSMOS and HALLMARK-DUAL study]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options